Tredegar (TG)
(Real Time Quote from BATS)
$8.00 USD
+0.80 (11.11%)
Updated Oct 16, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TG 8.00 +0.80(11.11%)
Will TG be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TG
The Zacks Analyst Blog Highlights Broadcom, Novo Nordisk, ConocoPhillips, Smith-Midland Corp. and Tredegar
Top Research Reports for Broadcom, Novo Nordisk & ConocoPhillips
TG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tredegar (TG) Q2 Earnings Rise Y/Y on Strength of PE Films Unit
Zacks Initiates Coverage of Tredegar With Underperform Recommendation
Other News for TG
Tredegar’s Terphane Sale Approved by Brazilian Authority
Brazil regulator approves sale of Tredegar's Terphane unit to Oben Group
Tredegar trading resumes
Tredegar receives Brazilian CADE approval for sale of Terphane business unit
Tredegar trading halted, news pending